Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4211913 | 0.90 | KCNH2 (0.50) | CCR3SIGMAR1CCR4KCNH2 | |
| SCHEMBL4212647 | 0.81 | CCR5 (0.39) | CCR3KCNH2 | |
| SCHEMBL4212648 | 0.80 | CCR5 (0.44) | — | |
| SCHEMBL4199649 | 0.80 | CCR5 (0.34) | ACHE | |
| SCHEMBL4217152 | 0.79 | ACHE (0.41) | ACHE | |
| SCHEMBL4218442 | 0.79 | MCHR1 (0.44) | MCHR1SIGMAR1 | |
| SCHEMBL4218448 | 0.79 | MCHR1 (0.44) | MCHR1SIGMAR1 | |
| SCHEMBL4202369 | 0.79 | HTR4 (0.40) | — | |
| SCHEMBL13928780 | 0.79 | CYP2D6 (0.46) | DRD4 | |
| SCHEMBL4209657 | 0.78 | KCNH2 (0.53) | ACHESIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488738-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-7488738-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-7488738-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-6998401-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | SUNTORY LIMITED (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050245574-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1045693-B1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-6559146-B1 | Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins | SUNTORY LIMITED (JP) | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245574-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | CAMK2A, CAMK2B, SLC1A2 | MCHR1 2598/4885CCR3 3182/4885ACHE 2352/4885 |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | FABP7, SLC1A2, CAMK2A | MCHR1 2661/4885CCR3 2699/4885ACHE 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.